<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833335</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190736</org_study_id>
    <nct_id>NCT04833335</nct_id>
  </id_info>
  <brief_title>ASL in Brain Metastasis MRI Following Gamma Knife Treatment</brief_title>
  <acronym>GK-ASL</acronym>
  <official_title>ASL in Diagnostics of Tumor Progression Versus Radionecrosis in Brain Metastasis Following Gamma Knife Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists&#xD;
      to distinguish brain metastasis progression versus radionecrosis following gamma-knife&#xD;
      treatment.&#xD;
&#xD;
      The primary target of the study is to establish the diagnostic performances (specificity,&#xD;
      sensitivity) of quantitative measures of ASL in brain metastases suspected of&#xD;
      progression/radionecrosis after GK treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metastasis progression versus radionecrosis following GK treatment can sometimes be&#xD;
      difficult to distinguish. 60 patients will be included in this prospective, monocentric&#xD;
      study. 3 MRI (baseline, 1month and 6 month follow-ups) will be performed. Two&#xD;
      neuroradiologists will blindly analyse the MRIs comparing ASL sensibility and specificity to&#xD;
      the standard morphological evaluation and T2 perfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of ASL quantitative analysis in brain metastasis following GK treatment : tumor perfusion with quantitative measurement (one value) of RCBF (relative cerebral blood flow) on the ASL sequence</measure>
    <time_frame>Evolution between Baseline MRI, 1 and 6 month follow up MRI</time_frame>
    <description>Quantitative analysis (rCBF) of the evolution of brain metastasis between the initiation of treatment and 6 months after.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASL Perfusion: Cerebral blood flow measurements</measure>
    <time_frame>Baseline MRI, 1 and 6 month follow up MRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interreader correlation</measure>
    <time_frame>Baseline MRI, 1 and 6 month follow-up MRI</time_frame>
    <description>Two neuroradiologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological analysis of the lesions</measure>
    <time_frame>Baseline MRI, 1 and 6 month follow-up MRI</time_frame>
    <description>Lesion size, oedema</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion visit, 1 month later, 6 month later</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI perfusion sequence</intervention_name>
    <description>Quantitative analysis</description>
    <arm_group_label>Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus</arm_group_label>
    <other_name>Arterial Spin Labeling (ASL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis from histologically proven tumor&#xD;
&#xD;
          -  GK treatment within 4 month prior to the inclusion&#xD;
&#xD;
          -  Lesions suspected of progression/ radionecrosis :&#xD;
&#xD;
             i.e.≥ 25% of the size progression&#xD;
&#xD;
          -  Lesion size: gadolinium enhanced part of the tumour ≥1 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Medical history of primitive brain tumour&#xD;
&#xD;
          -  MRI incompatibility/ medical history of contrast agent allergy&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Patient unable to consent&#xD;
&#xD;
          -  Epilepsia/recent stroke&#xD;
&#xD;
          -  Patients participating in other studies&#xD;
&#xD;
          -  Patients without health care insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalia SHOR, MD</last_name>
    <phone>+330661884335</phone>
    <email>shor.natalia@icloud.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASL</keyword>
  <keyword>MRI</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Gamma knife</keyword>
  <keyword>Radionecrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

